Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis StudyYou must be logged in to view this page.
Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 YearYou must be logged in to view this page.
The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic healthYou must be logged in to view this page.
From Doctor To Investor: How My MBA Kickstarted An Exciting Career In Life Sciences Venture CapitalYou must be logged in to view this page.
Sound Bioventures appoints Fredrik Lehmann as its first Entrepreneur-in-ResidenceYou must be logged in to view this page.
At the intersection of entrepreneurship, life science, & patient needsYou must be logged in to view this page.
Bringing everything together for an autoimmunity game changerYou must be logged in to view this page.
AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory DiseasesYou must be logged in to view this page.
Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transferYou must be logged in to view this page.
Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated DiseasesYou must be logged in to view this page.
Reaching the next level of creating novel therapies for genetic diseasesYou must be logged in to view this page.